focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Share News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.825
Bid: 1.80
Ask: 1.85
Change: 0.048 (2.46%)
Spread: 0.05 (2.778%)
Open: 1.95
High: 1.998
Low: 1.998
Prev. Close: 1.95
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: UK NICE backs Genedrive test; Corero renews deal

Wed, 03rd Apr 2024 10:47

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Genedrive PLC, up 57% at 5.90 pence, 12-month range 2.56p-34.90p. The molecular diagnostics company announces that the UK's National Institute for Health & Care Excellence has recommended in draft guidance that Genedrive's CYP2C19-ID test should be used as the point-of-care test of choice for ischemic stroke and transient ischaemic attack patients. Chief Executive Officer James Cheek comments: "We are delighted to receive this recommendation from NICE for our CYP2C19 point of care pharmacogenetic test. The NHS has done significant work on both strokes and mini strokes, with campaigns for face, arms, speech and time, and promoting changing lifestyles to prevent a stroke. This guidance is just the next step in stroke management, ensuring that if you have a stroke, specifically related to a disruption of the blood flow, that the medicine given has a positive effect....With MT-RNR1 getting a NICE EVA conditional recommendation last year, further funding applied for to achieve a full recommendation this year, a strategy in place to achieve US Food & Drug Administration approval and sales being realised from new customers in 2024 we feel there is growing momentum within the group's POC pharmacogenetic testing strategy."

----------

Corero Network Security PLC, up 15% at 10.36p, 12-month range 5.50p-10.65p. The cybersecurity provider specialising in distributed denial-of-service protection solutions wins a contract renewal worth over USD2 million over three years with an unnamed US-based software-as-a-service provider, expanding its partnership and marking one of Corero's "largest" single transactions to date. Corero says the deal reinforces its strong customer retention track record, while "significantly" enhancing the customer's distributed denial-of-service protection infrastructure. This ensure the "security and service availability of the SaaS provider's worldwide operations and reinforcing its resilience against the burgeoning range of cyberthreats". Corero Chief Executive Officer Carl Herberger comments: "We are committed to providing cutting-edge, reliable DDoS protection solutions to support our customers' growth and operational security and will continue to explore new business and mandate expansion opportunities as we aim to both broaden and strengthen our client portfolio."

----------

AIM - LOSERS

----------

Peel Hunt Ltd, down 5.1% at 120.00p, 12-month range 78.00p-142.00p. The investment bank expects a full-year loss as increasing costs offset a modest rise in revenue. In a trading statement for the year to March 31, Peel Hunt says revenue is expected to be consistent with market expectations at around GBP85.5 million, up 3.9% from GBP82.3 million last year. This growth comes despite equity capital markets "remaining challenging" throughout the financial year. Looking ahead, the firm expects market trading volumes to remain low until there are meaningful signs of recovery in the UK economy and fund outflows reverse. It notes whilst initial public offering activity in the UK remains muted, there has been more activity in Europe and sentiment towards IPOs is improving in the UK, with investors increasingly willing to engage in relation to high quality companies.

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
10 May 2024 12:10

IN BRIEF: Genedrive completes placing portion of GBP6 million raise

Genedrive PLC - Manchester-based pharmacogenetic testing - Completes placing of 138.8 million new shares at 1.5 pence each, raising GBP2.1 million. The placing is part of an overall equity raise being run by Peel Hunt LLP. Late Thursday, Genedrive had said it will try to raise a minimum of GBP6.0 million, including offers to retail investors. If that minimum is not reached, then only the firm placing will go ahead. The placing and retail offer prices will be the same and represent a more than 50% discount to Genedrive's closing price on Thursday. The placing shares will almost double Genedrive's total, and the retail offers could see another 376.4 million new shares issued. It expects to call a general meeting for May 31 to approve the share issue.

Read more
10 May 2024 10:59

AIM WINNERS & LOSERS: Polarean wins deal; Genedrive completes placing

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
10 May 2024 07:00

IN BRIEF: Genedrive aims to raise at least GBP6 million in share offer

Genedrive PLC - Manchester-based pharmacogenetic testing company - Seeks to raise a minimum of GBP6.0 million from an offer of new shares at 1.5 pence each. The announcement is made after the London market close on Thursday, and the price represents a more than 50% discount to Genedrive's closing price. The equity raise will be split into a firm placing of shares for GBP2.5 million, an offer to new and existing retail investors via the REX platform for GBP3.5 million, and an open offer to existing shareholders for GBP2.1 million. Genedrive says that if the GBP6.0 million minimum target is not reached, then only the firm placing will go ahead. The share sale is being run by broker Peel Hunt LLP.

Read more
24 Apr 2024 17:26

Genedrive enters clinical trial deal in US for MT-RNR1 US approval

(Alliance News) - Genedrive PLC on Wednesday said it has entered into a clinical trial agreement to support clinical studies to progress the regulatory approval of its MT-RNR1 product.

Read more
3 Apr 2024 16:54

LONDON MARKET CLOSE: FTSE 100 up thanks to US economic data

(Alliance News) - Stock prices in London closed mostly higher on Wednesday, after some data from the US reinforced the interest rate cut trajectory across the Atlantic.

Read more
3 Apr 2024 13:54

Genedrive shares jump on NICE test recommendation

(Sharecast News) - Genedrive shares were surging on Wednesday, after it received a significant endorsement from the UK's National Institute for Health and Care Excellence (NICE) regarding its 'CYP2C19-ID' test.

Read more
3 Apr 2024 11:49

Genedrive shares surge as UK's NICE backs test for ischaemic stroke

(Alliance News) - Genedrive PLC on Wednesday praised the National Health Service's work on strokes and mini strokes as a test by the company received a recommendation from the UK's National Institute for Health & Care Excellence.

Read more
28 Mar 2024 14:35

EARNINGS AND TRADING: 888 advances US exit; Arrow ups reserve estimate

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
15 Mar 2024 14:27

Genedrive receives R&D tax credit, plans fundraise

(Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive announced the receipt of a research and development tax credit totalling £0.8m on Friday, taking its unaudited cash balances to £1.2m.

Read more
15 Mar 2024 13:50

Genedrive down as plans equity raise despite GBP800,000 tax credit

(Alliance News) - Genedrive PLC shares fell on Friday, after it said it has received a GBP800,000 research and development tax credit.

Read more
19 Feb 2024 18:57

TRADING UPDATES: Coro seals sale terms, Powerhouse makes good progress

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
19 Feb 2024 10:56

Genedrive set to apply for NICE EVA funding

(Sharecast News) - Genedrive shares rose on Monday, on the launch of the NICE early value assessment (EVA) evidence generation funding call, backed by the National Institute for Health and Care Research (NIHR).

Read more
19 Feb 2024 07:49

LONDON BRIEFING: MoneySupermarket credits Insurance for growth in 2023

(Alliance News) - Stocks in London are set to fall at Monday's open, as concerns over US inflation trends curb risk appetite, and damp hopes of interest rate cuts from the Federal Reserve.

Read more
2 Jan 2024 14:39

Genedrive confirms £0.6m equity prepayment drawdown

(Sharecast News) - Genedrive confirmed a planned £0.6m drawdown as part of its £5m equity prepayment facility on Tuesday, which it initially disclosed on 31 March 2023.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.